Pseudohyperaldosteroism during itraconazole treatment: a hitherto neglected clinically significant side effect

  title={Pseudohyperaldosteroism during itraconazole treatment: a hitherto neglected clinically significant side effect},
  author={Sandra Louise Brandi and Claus Larsen Feltoft and J{\o}rgen Serup and Ebbe Eldrup},
  journal={BMJ Case Reports},
We describe a married couple who both presented with hypertension and hypokalaemia. Both patients were diagnosed with pseudohyperaldosteronism triggered by the widely used antifungal drug itraconazole. This effect appears to be dose-dependent, where a daily intake of 100 mg itraconazole is enough to induce pseudohyperaldosteronism. Clinicians should be aware of pseudohyperaldosteronism as a possible adverse effect of itraconazole, and we recommend monitoring potassium levels and blood pressure… 
Antifungal Therapy with Azoles Induced the Syndrome of Acquired Apparent Mineralocorticoid Excess: a Literature and Database Analysis
The presented study supports very recent findings that posaconazole and itraconazoles, but not the other three azole antifungals investigated, are associated with AME and that the effects are dose-dependent, which allows for a dose de-escalation strategy and for substitution with fluconazole, isavuconazol, or voriconazole to resolve the adverse effects.
  • Medicine
    Reactions Weekly
  • 2021


Voriconazole-induced Severe Hyperkalemia Precipitated by Multiple Drug Interactions
A case of voriconazole-induced hyperkalemia in a patient administered concurrent medications to treat comorbidities is reported, and it is found that dronedarone might have increased the vorIconazole level in the second episode.
High-dose itraconazole in the treatment of severe mycoses
Eight patients with systemic mycoses and with prior treatment failures were treated with itraconazole (600 mg/day) for a mean duration of 5.5 months. All six patients without AIDS experienced
Secondary arterial hypertension: when, who, and how to screen?
R residue hypertension indicates either that some patients with secondary hypertension also have concomitant essential hypertension or that irreversible vascular remodelling has taken place, in patients with potentially reversible causes of hypertension, early detection and treatment are important to minimize/prevent irreversible changes in the vasculature and target organs.
The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline.
This guideline recommends that all patients with primary aldosteronism undergo adrenal computed tomography as the initial study in subtype testing and to exclude adrenocortical carcinoma and advises that an experienced radiologist should establish/exclude unilateral primary aldehydes using bilateral adrenal venous sampling.
Apparent mineralocorticoid excess.
In 1979, Ulick and New first coined the term Apparent Mineralocorticoid Excess (AME) for a syndrome of hypertension, hypokalaemia, suppressed renin-angiotensin-aldosterone axis and raised urinary
Itraconazole induced hypertension and hypokalemia: Mechanistic evaluation
Inhibition of 11β‐hydroxysteroid dehydrogenase 2 was demonstrated, and withholding itraconazole led to resolution of adverse effects that did not recur with voriconazole, adding to a growing body of evidence linking apparent mineralocorticoid excess with certain triazoles.